Global Liquid Biopsy Market

Liquid Biopsy Comprehensive Study by Type (Assays Kits, Instruments, Services), Application (Oncology (Lung Cancer. Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Cancer), Non-Cancer Application), Clinical Application (Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring Orthopedics), Circulating Biomarker Type (Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Cell-Free DNA (cfDNA), Extracellular Vesicles (EVs), Other Circulating Biomarkers), End-User (Reference Laboratories, Hospitals and Physician Laboratories, Academic and Research Centers, Other) Players and Region - Global Market Outlook to 2025

Liquid Biopsy Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 17.4%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
A liquid biopsy is used to help find cancer at early stage, using sample of blood of tumor circulating within blood or pieces of DNA of the tumor. It is non-invasive alternative to surgical biopsy. Rapid advancement in the liquid biopsy for enhancing the safety of cancer patients and for providing ease to the doctors during critical operations is expected to boost the growth opportunities for manufacturers of the liquid biopsy.According to AMA, the market for Liquid Biopsy is expected to register a CAGR of 17.4% during the forecast period to 2026. This growth is primarily driven by Surging incidences of lung cancer, gastrointestinal cancer, and breast cancer and Increasing inclination of physician and oncologists to opt for diagnostic with non-invasive procedures.

Globally, a noticeable market trend is evident Favorable government initiatives, and presence of huge cancer population base . Major Players, such as Biocept Inc. (United States), Qiagen N.V. (Netherlands), Roche Diagnostics (Switzerland), Bio-Rad Laboratories Inc. (United States), Myriad Genetics Inc (United States), Menarini-Silicon Biosystems (Italy), Trovagene Inc. (United States), Guardant Health Inc. (United States), Mdxhealth SA (Belgium) and Genomic Health Inc. (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In December 2018, Biocept Inc. a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, has entered into a Software License and Laboratory Data Supply Agreement with Prognos, Inc. an innovator in predicting disease by applying artificial intelligence (AI) to clinical laboratory diagnostics.

Market Drivers
  • Surging incidences of lung cancer, gastrointestinal cancer, and breast cancer
  • Increasing inclination of physician and oncologists to opt for diagnostic with non-invasive procedures

Market Trend
  • Favorable government initiatives, and presence of huge cancer population base
  • Rapid technological advancement in the liquid biopsy

Restraints
  • Higher cost associated with liquid biopsy compared to conventional techniques

Opportunities
The rising incidence of metastatic cancer across the globe
Challenges
Lack of awareness about liquid biopsy in underdeveloped nations

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Liquid Biopsy Study Sheds Light on
— The Liquid Biopsy Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Liquid Biopsy industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Liquid Biopsy industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Assays Kits
  • Instruments
  • Services
By Application
  • Oncology (Lung Cancer. Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Cancer)
  • Non-Cancer Application
By Clinical Application
  • Early Cancer Screening
  • Therapy Selection
  • Treatment Monitoring
  • Recurrence Monitoring Orthopedics

By Circulating Biomarker Type
  • Circulating Tumor Cells (CTCs)
  • Circulating Tumor DNA (ctDNA)
  • Cell-Free DNA (cfDNA)
  • Extracellular Vesicles (EVs)
  • Other Circulating Biomarkers

By End-User
  • Reference Laboratories
  • Hospitals and Physician Laboratories
  • Academic and Research Centers
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • Belgium
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Surging incidences of lung cancer, gastrointestinal cancer, and breast cancer
      • 3.2.2. Increasing inclination of physician and oncologists to opt for diagnostic with non-invasive procedures
    • 3.3. Market Challenges
      • 3.3.1. Lack of awareness about liquid biopsy in underdeveloped nations
    • 3.4. Market Trends
      • 3.4.1. Favorable government initiatives, and presence of huge cancer population base
      • 3.4.2. Rapid technological advancement in the liquid biopsy
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Liquid Biopsy, by Type, Application, Clinical Application, Circulating Biomarker Type, End-User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Liquid Biopsy (Value)
      • 5.2.1. Global Liquid Biopsy by: Type (Value)
        • 5.2.1.1. Assays Kits
        • 5.2.1.2. Instruments
        • 5.2.1.3. Services
      • 5.2.2. Global Liquid Biopsy by: Application (Value)
        • 5.2.2.1. Oncology (Lung Cancer. Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Cancer)
        • 5.2.2.2. Non-Cancer Application
      • 5.2.3. Global Liquid Biopsy by: Clinical Application (Value)
        • 5.2.3.1. Early Cancer Screening
        • 5.2.3.2. Therapy Selection
        • 5.2.3.3. Treatment Monitoring
        • 5.2.3.4. Recurrence Monitoring Orthopedics
      • 5.2.4. Global Liquid Biopsy by: Circulating Biomarker Type (Value)
        • 5.2.4.1. Circulating Tumor Cells (CTCs)
        • 5.2.4.2. Circulating Tumor DNA (ctDNA)
        • 5.2.4.3. Cell-Free DNA (cfDNA)
        • 5.2.4.4. Extracellular Vesicles (EVs)
        • 5.2.4.5. Other Circulating Biomarkers
      • 5.2.5. Global Liquid Biopsy by: End-User (Value)
        • 5.2.5.1. Reference Laboratories
        • 5.2.5.2. Hospitals and Physician Laboratories
        • 5.2.5.3. Academic and Research Centers
        • 5.2.5.4. Other
      • 5.2.6. Global Liquid Biopsy Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. Belgium
          • 5.2.6.3.5. United Kingdom
          • 5.2.6.3.6. Netherlands
          • 5.2.6.3.7. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Liquid Biopsy (Price)
      • 5.3.1. Global Liquid Biopsy by: Type (Price)
  • 6. Liquid Biopsy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Biocept Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Qiagen N.V. (Netherlands)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Roche Diagnostics (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bio-Rad Laboratories Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Myriad Genetics Inc (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Menarini-Silicon Biosystems (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Trovagene Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Guardant Health Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Mdxhealth SA (Belgium)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Genomic Health Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Liquid Biopsy Sale, by Type, Application, Clinical Application, Circulating Biomarker Type, End-User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Liquid Biopsy (Value)
      • 7.2.1. Global Liquid Biopsy by: Type (Value)
        • 7.2.1.1. Assays Kits
        • 7.2.1.2. Instruments
        • 7.2.1.3. Services
      • 7.2.2. Global Liquid Biopsy by: Application (Value)
        • 7.2.2.1. Oncology (Lung Cancer. Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Cancer)
        • 7.2.2.2. Non-Cancer Application
      • 7.2.3. Global Liquid Biopsy by: Clinical Application (Value)
        • 7.2.3.1. Early Cancer Screening
        • 7.2.3.2. Therapy Selection
        • 7.2.3.3. Treatment Monitoring
        • 7.2.3.4. Recurrence Monitoring Orthopedics
      • 7.2.4. Global Liquid Biopsy by: Circulating Biomarker Type (Value)
        • 7.2.4.1. Circulating Tumor Cells (CTCs)
        • 7.2.4.2. Circulating Tumor DNA (ctDNA)
        • 7.2.4.3. Cell-Free DNA (cfDNA)
        • 7.2.4.4. Extracellular Vesicles (EVs)
        • 7.2.4.5. Other Circulating Biomarkers
      • 7.2.5. Global Liquid Biopsy by: End-User (Value)
        • 7.2.5.1. Reference Laboratories
        • 7.2.5.2. Hospitals and Physician Laboratories
        • 7.2.5.3. Academic and Research Centers
        • 7.2.5.4. Other
      • 7.2.6. Global Liquid Biopsy Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. Belgium
          • 7.2.6.3.5. United Kingdom
          • 7.2.6.3.6. Netherlands
          • 7.2.6.3.7. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Liquid Biopsy (Price)
      • 7.3.1. Global Liquid Biopsy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Liquid Biopsy: by Type(USD Million)
  • Table 2. Liquid Biopsy Assays Kits , by Region USD Million (2015-2020)
  • Table 3. Liquid Biopsy Instruments , by Region USD Million (2015-2020)
  • Table 4. Liquid Biopsy Services , by Region USD Million (2015-2020)
  • Table 5. Liquid Biopsy: by Application(USD Million)
  • Table 6. Liquid Biopsy Oncology (Lung Cancer. Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Cancer) , by Region USD Million (2015-2020)
  • Table 7. Liquid Biopsy Non-Cancer Application , by Region USD Million (2015-2020)
  • Table 8. Liquid Biopsy: by Clinical Application(USD Million)
  • Table 9. Liquid Biopsy Early Cancer Screening , by Region USD Million (2015-2020)
  • Table 10. Liquid Biopsy Therapy Selection , by Region USD Million (2015-2020)
  • Table 11. Liquid Biopsy Treatment Monitoring , by Region USD Million (2015-2020)
  • Table 12. Liquid Biopsy Recurrence Monitoring Orthopedics , by Region USD Million (2015-2020)
  • Table 13. Liquid Biopsy: by Circulating Biomarker Type(USD Million)
  • Table 14. Liquid Biopsy Circulating Tumor Cells (CTCs) , by Region USD Million (2015-2020)
  • Table 15. Liquid Biopsy Circulating Tumor DNA (ctDNA) , by Region USD Million (2015-2020)
  • Table 16. Liquid Biopsy Cell-Free DNA (cfDNA) , by Region USD Million (2015-2020)
  • Table 17. Liquid Biopsy Extracellular Vesicles (EVs) , by Region USD Million (2015-2020)
  • Table 18. Liquid Biopsy Other Circulating Biomarkers , by Region USD Million (2015-2020)
  • Table 19. Liquid Biopsy: by End-User(USD Million)
  • Table 20. Liquid Biopsy Reference Laboratories , by Region USD Million (2015-2020)
  • Table 21. Liquid Biopsy Hospitals and Physician Laboratories , by Region USD Million (2015-2020)
  • Table 22. Liquid Biopsy Academic and Research Centers , by Region USD Million (2015-2020)
  • Table 23. Liquid Biopsy Other , by Region USD Million (2015-2020)
  • Table 24. South America Liquid Biopsy, by Country USD Million (2015-2020)
  • Table 25. South America Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 26. South America Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 27. South America Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 28. South America Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 29. South America Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 30. Brazil Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 31. Brazil Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 32. Brazil Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 33. Brazil Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 34. Brazil Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 35. Argentina Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 36. Argentina Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 37. Argentina Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 38. Argentina Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 39. Argentina Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 40. Rest of South America Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 41. Rest of South America Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 42. Rest of South America Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 43. Rest of South America Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 44. Rest of South America Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 45. Asia Pacific Liquid Biopsy, by Country USD Million (2015-2020)
  • Table 46. Asia Pacific Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 47. Asia Pacific Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 48. Asia Pacific Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 49. Asia Pacific Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 50. Asia Pacific Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 51. China Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 52. China Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 53. China Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 54. China Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 55. China Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 56. Japan Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 57. Japan Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 58. Japan Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 59. Japan Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 60. Japan Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 61. India Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 62. India Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 63. India Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 64. India Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 65. India Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 66. South Korea Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 67. South Korea Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 68. South Korea Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 69. South Korea Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 70. South Korea Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 71. Taiwan Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 72. Taiwan Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 73. Taiwan Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 74. Taiwan Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 75. Taiwan Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 76. Australia Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 77. Australia Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 78. Australia Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 79. Australia Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 80. Australia Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 81. Rest of Asia-Pacific Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 82. Rest of Asia-Pacific Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 83. Rest of Asia-Pacific Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 84. Rest of Asia-Pacific Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 85. Rest of Asia-Pacific Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 86. Europe Liquid Biopsy, by Country USD Million (2015-2020)
  • Table 87. Europe Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 88. Europe Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 89. Europe Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 90. Europe Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 91. Europe Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 92. Germany Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 93. Germany Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 94. Germany Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 95. Germany Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 96. Germany Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 97. France Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 98. France Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 99. France Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 100. France Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 101. France Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 102. Italy Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 103. Italy Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 104. Italy Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 105. Italy Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 106. Italy Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 107. Belgium Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 108. Belgium Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 109. Belgium Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 110. Belgium Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 111. Belgium Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 112. United Kingdom Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 113. United Kingdom Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 114. United Kingdom Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 115. United Kingdom Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 116. United Kingdom Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 117. Netherlands Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 118. Netherlands Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 119. Netherlands Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 120. Netherlands Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 121. Netherlands Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 122. Rest of Europe Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 123. Rest of Europe Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 124. Rest of Europe Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 125. Rest of Europe Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 126. Rest of Europe Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 127. MEA Liquid Biopsy, by Country USD Million (2015-2020)
  • Table 128. MEA Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 129. MEA Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 130. MEA Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 131. MEA Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 132. MEA Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 133. Middle East Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 134. Middle East Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 135. Middle East Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 136. Middle East Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 137. Middle East Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 138. Africa Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 139. Africa Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 140. Africa Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 141. Africa Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 142. Africa Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 143. North America Liquid Biopsy, by Country USD Million (2015-2020)
  • Table 144. North America Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 145. North America Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 146. North America Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 147. North America Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 148. North America Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 149. United States Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 150. United States Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 151. United States Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 152. United States Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 153. United States Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 154. Canada Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 155. Canada Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 156. Canada Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 157. Canada Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 158. Canada Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 159. Mexico Liquid Biopsy, by Type USD Million (2015-2020)
  • Table 160. Mexico Liquid Biopsy, by Application USD Million (2015-2020)
  • Table 161. Mexico Liquid Biopsy, by Clinical Application USD Million (2015-2020)
  • Table 162. Mexico Liquid Biopsy, by Circulating Biomarker Type USD Million (2015-2020)
  • Table 163. Mexico Liquid Biopsy, by End-User USD Million (2015-2020)
  • Table 164. Liquid Biopsy: by Type(USD/Units)
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Company Basic Information, Sales Area and Its Competitors
  • Table 174. Company Basic Information, Sales Area and Its Competitors
  • Table 175. Liquid Biopsy: by Type(USD Million)
  • Table 176. Liquid Biopsy Assays Kits , by Region USD Million (2021-2026)
  • Table 177. Liquid Biopsy Instruments , by Region USD Million (2021-2026)
  • Table 178. Liquid Biopsy Services , by Region USD Million (2021-2026)
  • Table 179. Liquid Biopsy: by Application(USD Million)
  • Table 180. Liquid Biopsy Oncology (Lung Cancer. Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Cancer) , by Region USD Million (2021-2026)
  • Table 181. Liquid Biopsy Non-Cancer Application , by Region USD Million (2021-2026)
  • Table 182. Liquid Biopsy: by Clinical Application(USD Million)
  • Table 183. Liquid Biopsy Early Cancer Screening , by Region USD Million (2021-2026)
  • Table 184. Liquid Biopsy Therapy Selection , by Region USD Million (2021-2026)
  • Table 185. Liquid Biopsy Treatment Monitoring , by Region USD Million (2021-2026)
  • Table 186. Liquid Biopsy Recurrence Monitoring Orthopedics , by Region USD Million (2021-2026)
  • Table 187. Liquid Biopsy: by Circulating Biomarker Type(USD Million)
  • Table 188. Liquid Biopsy Circulating Tumor Cells (CTCs) , by Region USD Million (2021-2026)
  • Table 189. Liquid Biopsy Circulating Tumor DNA (ctDNA) , by Region USD Million (2021-2026)
  • Table 190. Liquid Biopsy Cell-Free DNA (cfDNA) , by Region USD Million (2021-2026)
  • Table 191. Liquid Biopsy Extracellular Vesicles (EVs) , by Region USD Million (2021-2026)
  • Table 192. Liquid Biopsy Other Circulating Biomarkers , by Region USD Million (2021-2026)
  • Table 193. Liquid Biopsy: by End-User(USD Million)
  • Table 194. Liquid Biopsy Reference Laboratories , by Region USD Million (2021-2026)
  • Table 195. Liquid Biopsy Hospitals and Physician Laboratories , by Region USD Million (2021-2026)
  • Table 196. Liquid Biopsy Academic and Research Centers , by Region USD Million (2021-2026)
  • Table 197. Liquid Biopsy Other , by Region USD Million (2021-2026)
  • Table 198. South America Liquid Biopsy, by Country USD Million (2021-2026)
  • Table 199. South America Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 200. South America Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 201. South America Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 202. South America Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 203. South America Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 204. Brazil Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 205. Brazil Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 206. Brazil Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 207. Brazil Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 208. Brazil Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 209. Argentina Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 210. Argentina Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 211. Argentina Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 212. Argentina Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 213. Argentina Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 214. Rest of South America Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 215. Rest of South America Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 216. Rest of South America Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 217. Rest of South America Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 218. Rest of South America Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 219. Asia Pacific Liquid Biopsy, by Country USD Million (2021-2026)
  • Table 220. Asia Pacific Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 221. Asia Pacific Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 222. Asia Pacific Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 223. Asia Pacific Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 224. Asia Pacific Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 225. China Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 226. China Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 227. China Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 228. China Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 229. China Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 230. Japan Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 231. Japan Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 232. Japan Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 233. Japan Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 234. Japan Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 235. India Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 236. India Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 237. India Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 238. India Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 239. India Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 240. South Korea Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 241. South Korea Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 242. South Korea Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 243. South Korea Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 244. South Korea Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 245. Taiwan Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 246. Taiwan Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 247. Taiwan Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 248. Taiwan Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 249. Taiwan Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 250. Australia Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 251. Australia Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 252. Australia Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 253. Australia Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 254. Australia Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 255. Rest of Asia-Pacific Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 256. Rest of Asia-Pacific Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 257. Rest of Asia-Pacific Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 258. Rest of Asia-Pacific Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 259. Rest of Asia-Pacific Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 260. Europe Liquid Biopsy, by Country USD Million (2021-2026)
  • Table 261. Europe Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 262. Europe Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 263. Europe Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 264. Europe Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 265. Europe Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 266. Germany Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 267. Germany Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 268. Germany Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 269. Germany Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 270. Germany Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 271. France Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 272. France Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 273. France Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 274. France Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 275. France Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 276. Italy Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 277. Italy Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 278. Italy Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 279. Italy Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 280. Italy Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 281. Belgium Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 282. Belgium Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 283. Belgium Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 284. Belgium Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 285. Belgium Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 286. United Kingdom Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 287. United Kingdom Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 288. United Kingdom Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 289. United Kingdom Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 290. United Kingdom Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 291. Netherlands Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 292. Netherlands Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 293. Netherlands Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 294. Netherlands Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 295. Netherlands Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 296. Rest of Europe Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 297. Rest of Europe Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 298. Rest of Europe Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 299. Rest of Europe Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 300. Rest of Europe Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 301. MEA Liquid Biopsy, by Country USD Million (2021-2026)
  • Table 302. MEA Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 303. MEA Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 304. MEA Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 305. MEA Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 306. MEA Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 307. Middle East Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 308. Middle East Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 309. Middle East Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 310. Middle East Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 311. Middle East Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 312. Africa Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 313. Africa Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 314. Africa Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 315. Africa Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 316. Africa Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 317. North America Liquid Biopsy, by Country USD Million (2021-2026)
  • Table 318. North America Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 319. North America Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 320. North America Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 321. North America Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 322. North America Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 323. United States Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 324. United States Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 325. United States Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 326. United States Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 327. United States Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 328. Canada Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 329. Canada Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 330. Canada Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 331. Canada Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 332. Canada Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 333. Mexico Liquid Biopsy, by Type USD Million (2021-2026)
  • Table 334. Mexico Liquid Biopsy, by Application USD Million (2021-2026)
  • Table 335. Mexico Liquid Biopsy, by Clinical Application USD Million (2021-2026)
  • Table 336. Mexico Liquid Biopsy, by Circulating Biomarker Type USD Million (2021-2026)
  • Table 337. Mexico Liquid Biopsy, by End-User USD Million (2021-2026)
  • Table 338. Liquid Biopsy: by Type(USD/Units)
  • Table 339. Research Programs/Design for This Report
  • Table 340. Key Data Information from Secondary Sources
  • Table 341. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Liquid Biopsy: by Type USD Million (2015-2020)
  • Figure 5. Global Liquid Biopsy: by Application USD Million (2015-2020)
  • Figure 6. Global Liquid Biopsy: by Clinical Application USD Million (2015-2020)
  • Figure 7. Global Liquid Biopsy: by Circulating Biomarker Type USD Million (2015-2020)
  • Figure 8. Global Liquid Biopsy: by End-User USD Million (2015-2020)
  • Figure 9. South America Liquid Biopsy Share (%), by Country
  • Figure 10. Asia Pacific Liquid Biopsy Share (%), by Country
  • Figure 11. Europe Liquid Biopsy Share (%), by Country
  • Figure 12. MEA Liquid Biopsy Share (%), by Country
  • Figure 13. North America Liquid Biopsy Share (%), by Country
  • Figure 14. Global Liquid Biopsy: by Type USD/Units (2015-2020)
  • Figure 15. Global Liquid Biopsy share by Players 2020 (%)
  • Figure 16. Global Liquid Biopsy share by Players (Top 3) 2020(%)
  • Figure 17. Global Liquid Biopsy share by Players (Top 5) 2020(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. Biocept Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Biocept Inc. (United States) Revenue: by Geography 2020
  • Figure 21. Qiagen N.V. (Netherlands) Revenue, Net Income and Gross profit
  • Figure 22. Qiagen N.V. (Netherlands) Revenue: by Geography 2020
  • Figure 23. Roche Diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Roche Diagnostics (Switzerland) Revenue: by Geography 2020
  • Figure 25. Bio-Rad Laboratories Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Bio-Rad Laboratories Inc. (United States) Revenue: by Geography 2020
  • Figure 27. Myriad Genetics Inc (United States) Revenue, Net Income and Gross profit
  • Figure 28. Myriad Genetics Inc (United States) Revenue: by Geography 2020
  • Figure 29. Menarini-Silicon Biosystems (Italy) Revenue, Net Income and Gross profit
  • Figure 30. Menarini-Silicon Biosystems (Italy) Revenue: by Geography 2020
  • Figure 31. Trovagene Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Trovagene Inc. (United States) Revenue: by Geography 2020
  • Figure 33. Guardant Health Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Guardant Health Inc. (United States) Revenue: by Geography 2020
  • Figure 35. Mdxhealth SA (Belgium) Revenue, Net Income and Gross profit
  • Figure 36. Mdxhealth SA (Belgium) Revenue: by Geography 2020
  • Figure 37. Genomic Health Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Genomic Health Inc. (United States) Revenue: by Geography 2020
  • Figure 39. Global Liquid Biopsy: by Type USD Million (2021-2026)
  • Figure 40. Global Liquid Biopsy: by Application USD Million (2021-2026)
  • Figure 41. Global Liquid Biopsy: by Clinical Application USD Million (2021-2026)
  • Figure 42. Global Liquid Biopsy: by Circulating Biomarker Type USD Million (2021-2026)
  • Figure 43. Global Liquid Biopsy: by End-User USD Million (2021-2026)
  • Figure 44. South America Liquid Biopsy Share (%), by Country
  • Figure 45. Asia Pacific Liquid Biopsy Share (%), by Country
  • Figure 46. Europe Liquid Biopsy Share (%), by Country
  • Figure 47. MEA Liquid Biopsy Share (%), by Country
  • Figure 48. North America Liquid Biopsy Share (%), by Country
  • Figure 49. Global Liquid Biopsy: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Biocept Inc. (United States)
  • Qiagen N.V. (Netherlands)
  • Roche Diagnostics (Switzerland)
  • Bio-Rad Laboratories Inc. (United States)
  • Myriad Genetics Inc (United States)
  • Menarini-Silicon Biosystems (Italy)
  • Trovagene Inc. (United States)
  • Guardant Health Inc. (United States)
  • Mdxhealth SA (Belgium)
  • Genomic Health Inc. (United States)
Additional players considered in the study are as follows:
Raindance Technologies Inc (United States) , Thermo Fisher Scientific Inc. (United States) , Illumina Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2021 232 Pages 95 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Liquid Biopsy Market Quantitative research analysis
Global Liquid Biopsy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Liquid Biopsy Market Report?

Have a Query? Click Here

Other Related Reports

Airway Stent / Lung Stent Comprehensive Study by Type (Metallic Airway Stent, Nitinol Airway Stent, Stainless steel Airway Stent, Silicone Airway Stent, Hybrid Airway Stent, Others), Application (Hos...
$ 3650
Sponge Forceps Comprehensive Study by Type (Toothed Type Sponge Forceps, Toothless Type Sponge Forceps), Application (Orthopedic, Abdominal, Gynecology, Neurosurgery, Microsurgery, Others), Distribut...
$ 3750
Nanotechnology in Medical Devices Comprehensive Study by Type (Active Implantable Devices, Biochips, Implantable Materials, Medical Textiles, Wound Dressings, Others), Application (Diagnostic, Therap...
$ 3800
Electrosurgery Comprehensive Study by Type (Electrosurgical Generators, Electrosurgical Instruments & Accessories {Bipolar Electrosurgical Instruments, Monopolar Electrosurgical Instruments}, Argon &...
$ 3750
Brain Monitoring Comprehensive Study by Type (Computerized Tomography (CT) Scanners, Magnetic Resonance Imaging (MRI) Scanners, Positron Emission Tomography (PET) Scanners, Electroencephalograph (EEG...
$ 3750
Intrauterine Devices Comprehensive Study by Type (Hormonal Intrauterine Devices, Non-Hormonal Intrauterine Devices), Application (Hospitals, Community Health Centres, Gynecological Clinics, Others), ...
$ 3450